Financial Data and Key Metrics Changes - Cryoport reported $41 million in revenue from continuing operations for Q1 2025, representing a 10% year-over-year growth and contributing to significant adjusted EBITDA improvement [10] - The company confirmed its revenue guidance for fiscal year 2025 in the range of $165 million to $172 million, indicating a 7.5% growth compared to fiscal year 2024 [13] Business Line Data and Key Metrics Changes - Life sciences services revenue increased by 17% year-over-year, driven by a 33% growth in support for commercial cell and gene therapies [10] - Life sciences services now account for 56% of total revenue, reflecting the increasing development and commercialization of cell and gene therapies [10] - The life sciences products business showed a 2% year-over-year growth, indicating demand stabilization [12] Market Data and Key Metrics Changes - Cryoport supported 19 commercial therapies and 711 clinical trials as of March 31, representing approximately 70% of cell and gene therapy trials [11] - The company anticipates up to 17 additional application filings and four therapy approvals for the remainder of 2025, indicating a robust pipeline [11] Company Strategy and Development Direction - The strategic partnership with DHL, involving the sale of Cryo PDP for an enterprise value of $195 million, is expected to enhance Cryoport's positioning in Asia Pacific and EMEA [12][13] - The partnership aims to leverage DHL's global scale and capabilities, allowing Cryoport to sharpen its focus on core life sciences service offerings in the regenerative medicine space [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth forecast despite potential tariff impacts, stating that they have taken steps to diversify the supply chain [14][15] - The company does not expect tariffs to significantly impact core support for clinical trials or commercial therapies [15] - Management remains optimistic about the commercial revenue ramp-up and the maturation of commercial therapies [44] Other Important Information - The company reported a significant increase in service gross margins year-over-year, with expectations for continued margin improvements [34] - The onboarding process for EntegraCell is progressing smoothly, with multiple commercial contracts already in place [65] Q&A Session Summary Question: Update on the launch of Entegrisel and client adoption - Management sees the market positively, with commercial revenue continuing to ramp and growth in clinical trials [20] Question: Contingent consideration impact on adjusted EBITDA - Management clarified that contingent consideration was backed out, and adjusted EBITDA improved significantly compared to Q1 of the previous year [29] Question: Response to potential tariffs and macro environment - Management indicated no significant tariff impact on cell and gene therapy, with continued commercial revenue growth [41][42] Question: Supply chain initiatives and margin improvements - Management stated that while they cannot quantify the impact of supply chain initiatives on margins, they expect strong gross margins to continue [54] Question: Impact of the new FDA director on therapy modalities - Management expressed optimism about the new FDA director's qualifications and the continued interest in cell and gene therapy [56] Question: Demand for new product launches - Management reported positive reception and ongoing adoption for new products, with expectations for substantial contributions in the future [62]

Financial Data and Key Metrics Changes - Cryoport reported $41 million in revenue from continuing operations for Q1 2025, representing a 10% year-over-year growth, contributing to significant adjusted EBITDA improvement [8] - The company confirmed its revenue guidance for fiscal year 2025 in the range of $165 million to $172 million, indicating a 7.5% growth relative to fiscal year 2024 [12][14] Business Line Data and Key Metrics Changes - Life sciences services revenue increased by 17% year-over-year, driven by a 33% growth in support for commercial cell and gene therapies [9][87] - Life sciences services now account for 56% of total revenue, reflecting the increasing development and commercialization of cell and gene therapies [9] Market Data and Key Metrics Changes - Cryoport supported 19 commercial therapies and 711 clinical trials as of March 31, representing approximately 70% of cell and gene therapy trials [10] - The company anticipates up to 17 additional application filings and four therapy approvals for the remainder of 2025, indicating a robust pipeline [11] Company Strategy and Development Direction - The strategic partnership with DHL, involving the sale of Cryo PDP for an enterprise value of $195 million, is expected to enhance Cryoport's positioning in Asia Pacific and EMEA [12] - The partnership aims to leverage DHL's global scale and capabilities, allowing Cryoport to sharpen its focus on core life sciences service offerings in the regenerative medicine space [12][84] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth forecast despite potential tariff impacts, stating that they have taken steps to diversify the supply chain [13] - The overall market for cell and gene therapies is viewed positively, with expectations of continued commercial revenue growth and a robust pipeline of therapies [19][20] Other Important Information - The company reported a significant increase in service gross margins, with expectations for continued expansion throughout 2025 [33] - Management noted that the new FDA director's conservative views are not expected to negatively impact the cell and gene therapy sector, emphasizing the importance of data in regulatory decisions [57][60] Q&A Session Summary Question: Update on Entegrisel launch and CGP trial growth - Management sees a positive market outlook with continued growth in commercial therapies and clinical trials, indicating a robust pipeline [19][20] Question: Contingent consideration impact on adjusted EBITDA - Management clarified that contingent consideration was backed out, and adjusted EBITDA improved significantly compared to Q1 of the previous year [28] Question: Steps to bolster shareholder value post-divestiture - Management plans to be prudent and opportunistic with cash allocation, considering stock buybacks due to undervaluation [29][30] Question: Service gross margins expansion - Management confirmed a significant increase in service gross margins and expects continued leverage from core services [33] Question: Performance of small vs. large pharma - Management reported balanced contributions from both biotech and large pharma, with a robust pipeline and continued interest in promising therapies [37] Question: Response to macroeconomic pressures and tariffs - Management indicated minimal impact from tariffs on cell and gene therapy, with ongoing commercial revenue growth [41][42] Question: Supply chain initiatives and margin improvement - Management emphasized that supply chain initiatives aim to protect margins rather than quantify specific improvements [55] Question: Impact of new FDA director on therapy approvals - Management expressed optimism regarding the new FDA director's qualifications and the continued progress of cell and gene therapies [57][60] Question: Demand for new product launches - Management reported positive reception and ongoing adoption of new products, with expectations for meaningful revenue contributions in the future [67]

[CEO Commentary and Business Highlights](index=1&type=section&id=CEO%20Commentary%20and%20Business%20Highlights) Cryoport started 2025 strongly with 10% revenue growth and improved adjusted EBITDA, driven by stabilizing demand and strategic partnerships - Revenue from continuing operations reached **$41.0 million**, growing **10% year-over-year**[3](index=3&type=chunk)[4](index=4&type=chunk)[7](index=7&type=chunk) - Commercial Cell & Gene Therapy revenue increased **33%** to **$7.2 million**[3](index=3&type=chunk)[4](index=4&type=chunk)[7](index=7&type=chunk) - The company supported **711 global clinical trials**, a net increase of **36 trials**[3](index=3&type=chunk)[4](index=4&type=chunk)[7](index=7&type=chunk) Key Financial and Operational Metrics | Metric | Q1 2025 Value | YoY Growth | | :--- | :--- | :--- | | Revenue from Continuing Operations | $41.0 million | 10% | | Commercial Cell & Gene Therapy Revenue | $7.2 million | 33% | | Global Clinical Trials Supported | 711 | +36 trials | - The company is seeing signs of demand stabilization in its Life Sciences Products business and new momentum in its Life Sciences Services business, which accounted for **56% of total revenue**[3](index=3&type=chunk)[4](index=4&type=chunk)[5](index=5&type=chunk) - A strategic partnership with DHL Group was announced, which includes the anticipated acquisition of CRYOPDP by DHL, expected to enhance operational reach in APAC and EMEA and allow Cryoport to focus on the regenerative medicine space[6](index=6&type=chunk)[12](index=12&type=chunk) - The company is advancing key initiatives like the IntegriCell™ Cryopreservation Solution and completing its Global Supply Chain Centers to diversify revenue streams[8](index=8&type=chunk) [Financial Performance](index=2&type=section&id=Financial%20Performance) Q1 2025 saw solid top-line growth, significant margin improvement, and a strengthened financial position, driven by Life Sciences Services [Revenue Analysis](index=2&type=section&id=Revenue%20Analysis) Q1 2025 total revenue from continuing operations grew 10.1% to $41.0 million, primarily led by Life Sciences Services Revenue from Continuing Operations | Revenue from Continuing Operations (in thousands) | Q1 2025 | Q1 2024 | % Change | | :--- | :--- | :--- | :--- | | Life Sciences Services | $22,865 | $19,485 | 17% | | - BioLogistics Solutions | $18,531 | $15,957 | 16% | | - BioStorage/BioServices | $4,334 | $3,528 | 23% | | Life Sciences Products | $18,175 | $17,806 | 2% | | **Total Revenue** | **$41,040** | **$37,291** | **10%** | - Revenue from the support of commercial Cell & Gene therapies increased by **33% year-over-year** to **$7.2 million**[4](index=4&type=chunk)[7](index=7&type=chunk)[10](index=10&type=chunk) [Profitability and Margins](index=4&type=section&id=Profitability%20and%20Margins) Q1 2025 profitability improved significantly, with gross margin expanding to 45.4% and net loss narrowing due to decreased operating expenses Gross Margin from Continuing Operations | Gross Margin from Continuing Operations | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Life Sciences Services | 47.9% | 43.5% | | Life Sciences Products | 42.3% | 37.0% | | **Total Gross Margin** | **45.4%** | **40.4%** | Key Profitability Metrics | Profitability Metric (in millions) | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Loss from Operations | $(9.5) | $(17.5) | | Net Loss | $(12.0) | $(18.9) | | Adjusted EBITDA | $(2.8) | $(6.7) | - Operating costs and expenses from continuing operations decreased by **13.7% year-over-year** to **$28.1 million**[14](index=14&type=chunk) [Financial Position](index=4&type=section&id=Financial%20Position) Cryoport maintained a strong financial position as of March 31, 2025, with $244.0 million in cash and $73.9 million available for share repurchases - The company held **$244.0 million** in cash, cash equivalents, and short-term investments as of March 31, 2025[16](index=16&type=chunk) Balance Sheet Highlights | Balance Sheet Highlights (in thousands) | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Total current assets | $411,276 | $341,572 | | Total assets | $699,844 | $703,493 | | Total current liabilities | $74,030 | $64,563 | | Total liabilities | $301,033 | $301,595 | | Total stockholders' equity | $398,811 | $401,898 | - As of March 31, 2025, **$73.9 million** remains available for repurchase under the company's two share repurchase programs[17](index=17&type=chunk) [Business and Operational Review](index=2&type=section&id=Business%20and%20Operational%20Review) Cryoport showed strong operational momentum, supporting 711 clinical trials and 19 commercial therapies, with Life Sciences Services driving growth [Clinical Trial Progress](index=3&type=section&id=Clinical%20Trial%20Progress) Cryoport's clinical trial support remains robust, with 711 global trials, including 79 in Phase 3, and anticipates significant regulatory milestones in 2025 Clinical Trials by Phase | Clinical Trials by Phase | March 31, 2025 | March 31, 2024 | | :--- | :--- | :--- | | Phase 1 | 304 | 286 | | Phase 2 | 328 | 312 | | Phase 3 | 79 | 77 | | **Total** | **711** | **675** | - The majority of trials are in the **Americas (544)**, followed by **EMEA (118)** and **APAC (49)**[11](index=11&type=chunk) - For the remainder of 2025, the company anticipates up to **17 additional application filings**, **4 new therapy approvals**, and **4 approvals for label/geographic expansions** for its clients[11](index=11&type=chunk) [Strategic Initiatives and Outlook](index=1&type=section&id=Strategic%20Initiatives%20and%20Outlook) Cryoport is executing strategic initiatives, including the DHL partnership and CRYOPDP divestiture, to focus on regenerative medicine and achieve positive adjusted EBITDA in 2025 [DHL Partnership and CRYOPDP Divestiture](index=1&type=section&id=DHL%20Partnership%20and%20CRYOPDP%20Divestiture) The DHL partnership and CRYOPDP divestiture will enhance global reach, provide capital, and sharpen Cryoport's focus on regenerative medicine - The partnership with DHL is expected to enhance the company's operational reach, especially in the **EMEA** and **APAC** regions, and reshape its competitive profile[6](index=6&type=chunk)[12](index=12&type=chunk) - The divestiture will provide a strong infusion of capital and allows the company to sharpen its organizational focus on the rapidly growing regenerative medicine space[6](index=6&type=chunk) - The transaction is subject to customary closing conditions and is expected to close in the **second or third quarter of 2025**[6](index=6&type=chunk)[12](index=12&type=chunk) [Fiscal 2025 Guidance](index=6&type=section&id=Fiscal%202025%20Guidance) Cryoport reiterates full-year 2025 guidance, projecting $165.0M-$172.0M organic revenue and a return to positive adjusted EBITDA during the year Fiscal Year 2025 Guidance | Fiscal Year 2025 Guidance | Range | YoY Growth | | :--- | :--- | :--- | | Total Organic Revenue | $165.0M - $172.0M | 5% - 10% | - The company remains confident that its current momentum and strategic actions will lead to a return to **positive adjusted EBITDA during 2025**[8](index=8&type=chunk) [Appendix](index=6&type=section&id=Appendix) This appendix provides supplementary information, including conference call details and non-GAAP financial measure reconciliations [Non-GAAP Reconciliations](index=11&type=section&id=Non-GAAP%20Reconciliations) The company provides GAAP to non-GAAP reconciliations, showing Q1 2025 adjusted EBITDA loss of $2.8 million from a GAAP loss of $9.0 million Reconciliation to Adjusted EBITDA | Reconciliation to Adjusted EBITDA (in thousands) | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | **GAAP loss from continuing operations** | **$(9,028)** | **$(15,035)** | | Depreciation and amortization expense | $6,134 | $5,747 | | Stock-based compensation expense | $3,064 | $4,666 | | Change in fair value of contingent consideration | $(5,178) | $293 | | Divestiture costs | $2,290 | $— | | Other adjustments (net) | $(181) | $(1,928) | | **Adjusted EBITDA from continuing operations** | **$(2,819)** | **$(6,657)** | - Adjusted EBITDA is used by management to assess operating results and for incentive compensation programs, excluding items like interest, taxes, depreciation, amortization, stock-based compensation, and other non-recurring or non-cash items[34](index=34&type=chunk)[35](index=35&type=chunk) [Conference Call Information](index=6&type=section&id=Conference%20Call%20Information) Cryoport held a conference call on May 7, 2025, at 5:00 p.m. ET for investors to discuss Q1 2025 results - A conference call for investors was held on Wednesday, **May 7, 2025, at 5:00 p.m. ET**[23](index=23&type=chunk)[24](index=24&type=chunk) - A live webcast and a replay of the call are available in the 'Investor Relations' section of the company's website[24](index=24&type=chunk)

Core Viewpoint - Cryoport, Inc. reported a strong start to 2025 with a revenue of $41.0 million for Q1, reflecting a 10% year-over-year growth, and expressed optimism for the full year due to stabilizing order patterns and increased engagement in its Life Sciences Services segment [2][6][19]. Financial Performance - Total revenue from continuing operations for Q1 2025 was $41.0 million, up from $37.3 million in Q1 2024, marking a 10.1% increase [14]. - Life Sciences Services revenue, which constituted 56% of total revenue, reached $22.9 million, a 17.3% increase year-over-year [14]. - Life Sciences Products revenue, representing 44% of total revenue, was $18.2 million, showing a 2.1% increase compared to the previous year [14]. - Adjusted EBITDA for Q1 2025 was a negative $2.8 million, an improvement from a negative $6.7 million in Q1 2024 [16][38]. - The net loss for Q1 2025 was $12.0 million, compared to a net loss of $18.9 million in Q1 2024 [24]. Business Segments - Revenue from commercial Cell & Gene therapies increased by 33% year-over-year, totaling $7.2 million [8][9]. - Life Sciences Services revenue increased by 17% year-over-year, driven by the development and commercialization of Cell & Gene-based therapies [3][9]. - BioStorage/BioServices revenue grew by 23% year-over-year, indicating strong demand for these services [7]. Strategic Developments - Cryoport announced a strategic partnership with DHL Group, which includes the anticipated acquisition of CRYOPDP, expected to close in Q2 or Q3 2025 [5][11]. - The partnership is expected to enhance operational reach in the APAC and EMEA regions and provide a strong infusion of capital [5][11]. Market Position and Outlook - The company supports 711 global clinical trials as of March 31, 2025, an increase of 36 trials from the previous year [9]. - The company anticipates continued growth in the regenerative medicine space and aims to return to positive adjusted EBITDA during 2025 [6][19].

Conference Call Information | Date: | Wednesday, May 7, 2025 | | --- | --- | | Time: | 5:00 p.m. ET | | Dial-in numbers: | 1-800-717-1738 (U.S.), 1-646-307-1865 (International) | | | Confirmation code:Request the "Cryoport Call" or Conference ID: 1180684 | | | 'Investor Relations' section at www.cryoportinc.com or click here. | | Live webcast: | Please allow 10 minutes prior to the call to visit this site to download and install any | | | necessary audio software. | The questions and answers call will be re ...

Cryoport, Inc. (NASDAQ:CYRX) Strategic Agreement and Transaction with DHL Group Call March 31, 2025 8:30 AM ET Company Participants Todd Fromer - Investor Relations, KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Tom Heinzen - Vice President, Corporate Development & Investor Relations Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Conference Call Participants Todd Fromer Thank you, operator. Before we begin today, I would like to remind everyone ...

Cryoport's Strategic Agreement and Transaction with DHL Group March 2025 © 2025 CRYOPORT, INC. 1 Forward Looking Statements Statements in this presentation which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans, or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, ...

BONN, Germany and NASHVILLE, Tenn., March 31, 2025 /PRNewswire/ -- DHL Group ("DHL"), the world's leading logistics provider, and Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global provider of supply chain solutions for the life sciences sector, are pleased to announce that DHL has acquired 100% of CRYOPDP, a leading specialty courier focused on clinical trials, biopharma, and cell and gene therapies. In this context, the companies also announced a strategic partnership to strengthen their supply chain se ...

Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software. The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until April 7, 2025. To access the re ...

NASHVILLE, Tenn., March 12, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today announced the launch of MVE Biological Solutions' ("MVE") High-Efficiency 800 C, the latest addition to its next-generation High-Efficiency ("HE") Series of cryogenic freezers. The HE 800 C combines ergonomic features and consistent performance in a compact size to meet the evolving needs of fertility clinics, biorepositories and ...